Anchen Zhang1, Ke Wang2, Cheng Zhou2, Zheng Gan3, Dongxia Ma4, Ping Ye5, Yuan Sun2, Jie Wu2, Xiaofan Huang2, Lingyun Ren2, Peng Deng2, Chuangyan Wu2, Zhang Yue2, Xiangchao Ding2, Jiuling Chen2, Jiahong Xia6. 1. Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Cardiovascular Medicine, Central Hospital of Wuhan, Wuhan, China. 2. Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 3. Department of Anesthesiology, Union Hospital, Tongji Medical College, Huazh'ong University of Science and Technology, Wuhan, China. 4. Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. 5. Department of Cardiovascular Medicine, Central Hospital of Wuhan, Wuhan, China. 6. Department of Cardiovascular Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Cardiovascular Medicine, Central Hospital of Wuhan, Wuhan, China; Department of Cardiovascular Surgery, Central Hospital of Wuhan, Wuhan, China. Electronic address: jiahong.xia@mail.hust.edu.cn.
Abstract
BACKGROUND: MicroRNAs (miRNAs) are integral for maintaining immune homeostasis and self-tolerance. The influence of miRNAs on T-cell differentiation and plasticity are critical in the development of chronic rejection of transplanted hearts. In this study, we sought to determine whether the knockout of miR-155 affects the development of cardiac allograft vasculopathy (CAV) in a murine model. METHODS: miRNA microarray and quantitative polymerase chain reaction (qPCR) analyses were performed for allograft neointimal lesion samples in chronic rejection. A model of heterotopic murine heart transplantation (bm12 to miR-155+/+ or miR-155-/- mice) was then used to analyze allograft survival, histology, mRNA expression and T-cell sub-populations in spleens. The accelerated experiments were performed by intraperitoneal injection of either recombinant interleukin-17A or phosphate-buffered saline (PBS) after heart transplantation. For the competitive transfer experiments, CD4+ splenocytes from wild-type (WT) or miR-155-/- mice were mixed and injected into Rag1-/- mice, and cardiac transplantation was performed after 24 hours. The differentiation of T-helper subsets (Th1/Th17/iTreg) was investigated in vitro. RESULTS: miR-155-/- mice showed resistance to cardiac rejection along with weakened T-cell-mediated inflammation, especially for Th17 cells. Recombinant IL-17A could restore this relieved injury. The competitive experiments implied that miR-155 plays a vital role in the stability of the Th17 phenotype. In vitro, we also demonstrated that miR-155-/- mice exhibit a defect in Th17 differentiation. CONCLUSIONS: miR-155 regulates Th1/Th17-related inflammation in chronic cardiac rejection and may be a potential therapeutic target to attenuate cardiac allograft rejection. Despite advancements in immunosuppressive therapy, the immunologic mechanisms responsible for allograft rejection remain an important issue for both clinicians and researchers. Allograft rejection is a T-cell-dependent phenomenon and is critically dependent on inflammation mediated by CD4+ Th subsets, including Th1, Th2, Th17, Th9 and regulatory T (Treg) cells.
BACKGROUND: MicroRNAs (miRNAs) are integral for maintaining immune homeostasis and self-tolerance. The influence of miRNAs on T-cell differentiation and plasticity are critical in the development of chronic rejection of transplanted hearts. In this study, we sought to determine whether the knockout of miR-155 affects the development of cardiac allograft vasculopathy (CAV) in a murine model. METHODS: miRNA microarray and quantitative polymerase chain reaction (qPCR) analyses were performed for allograft neointimal lesion samples in chronic rejection. A model of heterotopic murine heart transplantation (bm12 to miR-155+/+ or miR-155-/- mice) was then used to analyze allograft survival, histology, mRNA expression and T-cell sub-populations in spleens. The accelerated experiments were performed by intraperitoneal injection of either recombinant interleukin-17A or phosphate-buffered saline (PBS) after heart transplantation. For the competitive transfer experiments, CD4+ splenocytes from wild-type (WT) or miR-155-/- mice were mixed and injected into Rag1-/- mice, and cardiac transplantation was performed after 24 hours. The differentiation of T-helper subsets (Th1/Th17/iTreg) was investigated in vitro. RESULTS:miR-155-/- mice showed resistance to cardiac rejection along with weakened T-cell-mediated inflammation, especially for Th17 cells. Recombinant IL-17A could restore this relieved injury. The competitive experiments implied that miR-155 plays a vital role in the stability of the Th17 phenotype. In vitro, we also demonstrated that miR-155-/- mice exhibit a defect in Th17 differentiation. CONCLUSIONS:miR-155 regulates Th1/Th17-related inflammation in chronic cardiac rejection and may be a potential therapeutic target to attenuate cardiac allograft rejection. Despite advancements in immunosuppressive therapy, the immunologic mechanisms responsible for allograft rejection remain an important issue for both clinicians and researchers. Allograft rejection is a T-cell-dependent phenomenon and is critically dependent on inflammation mediated by CD4+ Th subsets, including Th1, Th2, Th17, Th9 and regulatory T (Treg) cells.
Authors: Marc Kästle; Sabine Bartel; Kerstin Geillinger-Kästle; Martin Irmler; Johannes Beckers; Bernhard Ryffel; Oliver Eickelberg; Susanne Krauss-Etschmann Journal: Immunology Date: 2017-07-28 Impact factor: 7.397
Authors: Byeongho Jung; Gerardo Ferrer; Pui Yan Chiu; Rukhsana Aslam; Anita Ng; Florencia Palacios; Michael Wysota; Martina Cardillo; Jonathan E Kolitz; Steven L Allen; Jacqueline C Barrientos; Kanti R Rai; Nicholas Chiorazzi; Barbara Sherry Journal: JCI Insight Date: 2022-06-22
Authors: Sangho Lim; Nancy C Kirkiles-Smith; Jordan S Pober; Alfred L M Bothwell; Je-Min Choi Journal: Biomaterials Date: 2018-08-21 Impact factor: 12.479
Authors: Sumi Westhofen; Marisa Jelinek; Leonie Dreher; Daniel Biermann; Jack Martin; Helga Vitzhum; Hermann Reichenspurner; Heimo Ehmke; Alexander Peter Schwoerer Journal: PLoS One Date: 2019-04-12 Impact factor: 3.240
Authors: Tereza Nováková; Táňa Macháčková; Jan Novák; Petr Hude; Július Godava; Víta Žampachová; Jan Oppelt; Filip Zlámal; Petr Němec; Helena Bedáňová; Ondřej Slabý; Julie Bienertová-Vašků; Lenka Špinarová; Jan Krejčí Journal: Cells Date: 2019-11-06 Impact factor: 6.600